Entera Bio holds annual meeting, expands share pool and authorized shares

Entera Bio Ltd. filed an 8-K on July 16, 2026 covering its 2026 Annual Meeting of Shareholders, which was held on July 14, 2026¹. The filing itself carries a report date of July 14, 2026, marking the earliest event reported, while the document was signed and submitted on July 16, 2026 by CEO Miranda Toledano.

Shareholders elected three Class III directors to three-year terms running until the 2029 annual meeting: Sean Ellis, Steven D. Rubin, and Geno H. Germano, according to the vote tallies disclosed in the filing.

The meeting also produced approval of an amendment to the company's 2018 Equity Incentive Plan. Specifically, shareholders approved an amendment to increase the number of ordinary shares issuable under the plan by a one-time amount of 2,500,000 ordinary shares.¹

Separately, investors approved a change to the company's charter. Shareholders approved an amendment to the Amended and Restated Articles of Association to increase the number of authorized ordinary shares from 140,010,000 to 350,000,000.¹ This articles amendment became effective upon shareholder approval at the annual meeting.¹

Other matters passed at the meeting included amended compensation terms for non-executive directors, share-based compensation grants tied to Steven D. Rubin and Geno J. Germano, one-time compensation grants for Sean Ellis and CEO Miranda Toledano, a non-binding advisory vote on named executive officer compensation, and ratification of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as independent auditor for fiscal year 2026. No other matters were considered or voted upon at the Annual Meeting.¹